{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:03Z","timestamp":1783401303574,"version":"3.54.6"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Given the limited therapeutic options for infections caused by carbapenem-resistant\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (CRKP) due to multidrug resistance, this study aimed to evaluate combination therapeutic strategies based on carbapenemase profiles and resistance phenotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>in vitro<\/jats:italic>\n                      activities of ceftazidime-avibactam (CZA) and polymyxin B (PMB)-based combinations was systematically evaluated against 139 CRKP isolates, including\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      carbapenemase (KPC) producing strains, New Delhi metallo-\u03b2-lactamase (NDM), and KPC and NDM co-producing carbapenem-resistant\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      strains (KN-CRKP). The combination effects of these antimicrobial combinations were assessed using the fractional inhibitory concentration index (FICI) and susceptibility breakpoint index (SBPI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among CZA-resistant KPC-CRKP isolates, combinations of CZA with \u03b2-lactams exhibited high synergy rates (79.7-86.5%). In PMB-resistant KPC-CRKP, PMB + CZA demonstrated substantially higher synergy rates (53.2%) than conventional PMB-carbapenem combinations (\u22643.8%). Against NDM-CRKP, CZA + aztreonam (ATM) showed synergistic activity in 83.3% of isolates. Notably, in KN-CRKP, CZA + ATM produced synergistic or additive effects in all isolates, despite resistance to the individual agents. SBPI analysis further suggested substantial antimicrobial enhancement in some combinations classified as indifferent by FICI, including PMB + tigecycline (TGC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Carbapenemase profiles substantially influence the efficacy of combination therapies against CRKP. CZA-based combinations, particularly those combined with \u03b2-lactams or ATM, demonstrated favorable\n                      <jats:italic>in vitro<\/jats:italic>\n                      activity against KPC and NDM-producing CRKP, while PMB in combination with CZA partially restored activity in PMB-resistance isolates. Notably, the CZA-ATM regimen showed consistently favorable activity against both NDM-CRKP and KPC-NDM co-producing isolates. These findings support the potential value of carbapenemase profile-guided combination therapy for optimizing treatment of highly resistant CRKP infections.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1866731","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:23:55Z","timestamp":1783398235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Carbapenemase-directed therapy: optimizing antibiotic combinations against carbapenem-resistant Klebsiella pneumoniae"],"prefix":"10.3389","volume":"16","author":[{"given":"Wen-bo","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital, Henan University People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fei","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Henan University People\u2019s Hospital, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Li","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Xuchang People\u2019s Hospital","place":["Xuchang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital, Henan University People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Li","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital, Henan University People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2025.117107","article-title":"Is the ceftazidime-avibactam plus aztreonam combination a solution for infections caused by metallo-\u03b2-lactamase producing carbapenem-resistant Enterobacterales? A call for further investigation","volume":"114","author":"Bawankar","year":"2026","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.16718\/j.1009-7708.2023.01.013","article-title":"Expert consensus on antimicrobial synergy testing and reporting for carbapenem-resistant Gram-negative bacteria","volume":"23","year":"2023","journal-title":"Chin. J. Infection Chemotherapy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.21037\/atm-22-236","article-title":"Population pharmacokinetics of polymyxin B: a systematic review","volume":"10","author":"Chen","year":"2022","journal-title":"Ann. Trans. Med."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02121-16","article-title":"Polymyxin B in combination with rifampin and meropenem against polymyxin B-resistant KPC-producing Klebsiella pneumoniae","volume":"61","author":"Diep","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s10096-019-03628-6","article-title":"Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae","volume":"38","author":"Gaibani","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Diseases: Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102599","article-title":"The transferability and evolution of NDM-1 and KPC-2 co-producing Klebsiella pneumoniae from clinical settings","volume":"51","author":"Gao","year":"2020","journal-title":"EBioMedicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s44280-025-00092-0","article-title":"Antimicrobial resistance profile of clinical isolates from hospitals across China: CHINET 2024 surveillance report","volume":"3","author":"Guo","year":"2025","journal-title":"One Health Adv."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s10096-024-04859-y","article-title":"Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime\/avibactam and aztreonam at a single center in Poland","volume":"43","author":"Guzek","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Diseases: Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1900734","DOI":"10.2807\/1560-7917.es.2019.24.50.1900734","article-title":"Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, north-eastern Germany, June to October 2019","volume":"24","author":"Haller","year":"2019","journal-title":"Euro Surveillance: Bull. Europeen sur les Maladies Transmissibles = Eur. Communicable Dis. Bull."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41564-024-01612-1","article-title":"Carbapenem-resistant Klebsiella pneumoniae capsular types, antibiotic resistance and virulence factors in China: a longitudinal, multi-centre study","volume":"9","author":"Hu","year":"2024","journal-title":"Nat. Microbiol."},{"key":"B12","unstructured":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically of the Web Page. Name of the Website. Of the Web Page. Name of the Website\n          \n          \n          \n          2024"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00344-20","article-title":"Evaluation of NG-Test Carba 5 for rapid phenotypic detection and differentiation of five common carbapenemase families: results of a multicenter clinical evaluation","volume":"58","author":"Jenkins","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/idr.s455146","article-title":"Clinical and molecular characteristics of patients with bloodstream infections caused by KPC and NDM co-producing carbapenem-resistant Klebsiella pneumoniae","volume":"17","author":"Li","year":"2024","journal-title":"Infection Drug Resistance"},{"key":"B15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/idr.s292431","article-title":"In vitro and in vivo effect of antimicrobial agent combinations against carbapenem-resistant Klebsiella pneumoniae with different resistance mechanisms in China","volume":"14","author":"Liu","year":"2021","journal-title":"Infection Drug Resistance"},{"key":"B16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tim.2023.10.006","article-title":"Plasmid-mediated colistin-resistance genes: mcr","volume":"32","author":"Liu","year":"2024","journal-title":"Trends Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12941-025-00797-5","article-title":"Clinical and microbiological characteristics of patients with ceftazidime\/avibactam-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains","volume":"24","author":"Liu","year":"2025","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10096-022-04523-3","article-title":"Successful treatment of ceftazidime\/avibactam combined with aztreonam in the NDM-producing Klebsiella pneumoniae bloodstream and intestinal infections in a NK\/T lymphoma patient with agranulocytosis during autologous hematopoietic stem cell transplantation: a case report","author":"Liu","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Diseases: Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/jac\/dkp384","article-title":"Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index","volume":"65","author":"Milne","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/antibiotics10080967","article-title":"Antimicrobial synergy testing: comparing the tobramycin and ceftazidime gradient diffusion methodology used in assessing synergy in cystic fibrosis-derived multidrug-resistant Pseudomonas aeruginosa","volume":"10","author":"Okoliegbe","year":"2021","journal-title":"Antibiotics (Basel Switzerland)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02483-20","article-title":"Trends of antimicrobial resistance and combination susceptibility testing of multidrug-resistant Pseudomonas aeruginosa isolates from cystic fibrosis patients: a 10-year update","volume":"65","author":"Okoliegbe","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/pathogens15020214","article-title":"In vitro evaluation of colistin-meropenem activity against XDR and PDR carbapenemase-producing Klebsiella pneumoniae and Acinetobacter baumannii","volume":"15","author":"Rezk","year":"2026","journal-title":"Pathog. (Basel Switzerland)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106426","article-title":"Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas","volume":"58","author":"Rodr\u00edguez-Santiago","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.2147\/idr.s400138","article-title":"Epidemiological and molecular characteristics of bla (NDM-1) and bla (KPC-2) co-occurrence carbapenem-resistant Klebsiella pneumoniae","volume":"16","author":"Rong","year":"2023","journal-title":"Infection Drug Resistance"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1033305","article-title":"Clinical carbapenem-resistant Klebsiella pneumoniae isolates simultaneously harboring bla (NDM-1), bla (OXA) types and qnrS genes from the Kingdom of Bahrain: resistance profile and genetic environment","volume":"12","author":"Shahid","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Diseases: An. Off. Publ. Infect. Dis. Soc. America"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00152-21","article-title":"Combined effect of polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant Klebsiella pneumoniae","volume":"9","author":"Tian","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","article-title":"Drug combinations: a strategy to extend the life of antibiotics in the 21st century","volume":"17","author":"Tyers","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s1473-3099(21)00399-6","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.868991","article-title":"Heteroresistance is associated with in vitro regrowth during colistin treatment in carbapenem-resistant Klebsiella pneumoniae","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J. Global Antimicrob. Resist."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1542029","article-title":"Study on the in vitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant Klebsiella pneumoniae","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1128\/aac.40.8.1914","article-title":"Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test","volume":"40","author":"White","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2026.103161","article-title":"Risk factors, clinical outcomes of patients with ceftazidime\/avibactam-resistant carbapenem-resistant Klebsiella pneumoniae infection and its potential resistant mechanisms","volume":"19","author":"Wu","year":"2026","journal-title":"J. Infection Public Health"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00107-24","article-title":"Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae","volume":"12","author":"Wu","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"136.e1","DOI":"10.1016\/j.cmi.2021.05.026","article-title":"Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC \u03b2-lactamase in China","volume":"28","author":"Xu","year":"2022","journal-title":"Clin. Microbiol. Infection: Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1093\/jac\/dkaf337","article-title":"Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime\/avibactam resistance during severe in vivo infection","volume":"80","author":"Yang","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.889020","article-title":"Clinical outcomes and microbiological characteristics of sequence type 11 Klebsiella pneumoniae infection","volume":"9","author":"Yang","year":"2022","journal-title":"Front. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.tim.2023.01.013","article-title":"Metallo-\u03b2-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery","volume":"31","author":"Yang","year":"2023","journal-title":"Trends Microbiol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1327230","article-title":"Exogenous glutathione reverses meropenem resistance in carbapenem-resistant Klebsiella pneumoniae","volume":"14","author":"Yi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-lactams strike back: ceftazidime-avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s15010-024-02324-8","article-title":"Ceftazidime\/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study","volume":"53","author":"Zhuang","year":"2025","journal-title":"Infection"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1866731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:24:04Z","timestamp":1783398244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1866731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":43,"alternative-id":["10.3389\/fcimb.2026.1866731"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1866731","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1866731"}}